2024-12-25 - Analysis Report
## Colgate-Palmolive Co. (CL) Stock Review

**1. Performance Comparison & Divergence:**

Colgate-Palmolive Co. (CL) is a multinational consumer goods company that manufactures and sells oral hygiene products, personal care products, and household cleaning products.

The cumulative return of CL (40.79%) significantly lags behind the S&P 500 (VOO) cumulative return (117.56%) over the analyzed period.  The difference is -76.8%, placing it at the 3.6th percentile of its historical range of divergence from the S&P 500 (-80.0% to 8.2%).  This indicates CL's underperformance relative to the broader market.  The provided Alpha and Beta analysis shows inconsistent performance, with periods of both outperformance (positive Alpha) and underperformance relative to the market (Beta consistently around 0.2).  The market capitalization fluctuates, but generally remains significant (42B - 75B).

**2. Recent Price Movement:**

* **Closing Price:** $91.91
* **Last Market Price:** $92.39
* **5-Day Moving Average:** $92.62
* **20-Day Moving Average:** $94.189
* **60-Day Moving Average:** $95.7621

The stock price is currently below all three moving averages, suggesting a potential downtrend.  The difference between the last market price and the closing price is minimal.

**3. Technical Indicators & Expected Return:**

* **RSI (34.41):** Suggests the stock is currently in oversold territory.
* **PPO (-0.1682):** Indicates bearish momentum.
* **20-Day Relative Divergence Change (+2.9):** Shows a recent short-term upward trend.

Given the RSI value, the negative PPO, and the stock price being below its moving averages, the current market sentiment appears bearish despite recent short-term gains.  The 0.0% expected return suggests that based on current data, long-term investment (2+ years) in CL is not expected to outperform the S&P 500. The Last Market price of $92.39 is not significantly different from the closing price and does not signal any extreme price movements (sharp rise or fall).

**4. Recent Earnings Analysis:**

The recent earnings data shows:

* **EPS:**  EPS has remained relatively stable around $0.86-$0.90 over the past four quarters, showing minor growth.
* **Revenue:** Revenue has fluctuated slightly, generally remaining around the $5 Billion mark. There's slight fluctuation rather than a clear upward trend.
* **Quarterly Comparison:** There is minor fluctuation but no significant growth or decline. There are no clear "beats" or "misses" based solely on the provided data.

**5. Financial Information Analysis:**

* **Revenue and Profitability:** Revenue is relatively stable but shows a minor decline in the most recent quarter. Profit margins have slightly decreased over the past year, indicating potential pressure on profitability.
* **Capital and Profitability:**  ROE shows extreme volatility, suggesting potential issues with the way equity is calculated or reported.  Further investigation would be needed to interpret these figures meaningfully.  Equity itself shows considerable fluctuation.

**6. News and Recent Issues:**

*  No recent (within the last two days) earnings news is provided.
*  No information on recent market outlook, analyst opinions, or performance highlights is given.  This is crucial information that would significantly impact the analysis.

**7. Overall Analysis:**

Colgate-Palmolive's performance has lagged significantly behind the S&P 500. While the RSI suggests oversold conditions, the negative PPO and position below its moving averages indicate bearish momentum. Recent earnings show stable, but not growing, EPS and revenue.  The highly volatile ROE figures raise serious questions about financial reporting or company activities.  Crucially, missing information on recent news, market outlook, and analyst opinions prevents a complete and accurate assessment.  The lack of clear upward trends in revenue or EPS and the inconsistent financial indicators suggest caution is warranted before considering investment.  Additional analysis and investigation of the unusually volatile ROE figures are necessary.

**8.  Recommendation:**

Given the incomplete data and the indicators suggesting underperformance, a more thorough investigation, including analysis of missing data and expert opinions, is strongly recommended before making any investment decisions regarding CL. The current information does not support a strong buy recommendation.
